What was studied?
Researchers screened drug-response scores against transcriptomic and clinical datasets from primary and recurrent glioma cohorts.
What did the researchers report?
The computational analysis prioritized sermorelin and linked predicted sensitivity with cell-cycle and immune-related signatures.
What are the limits?
Patients in these datasets were not shown to benefit from sermorelin administration. Predicted drug sensitivity is hypothesis-generating and requires experimental and clinical validation.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.